间变性淋巴瘤激酶(ALK)阳性腺癌17年后复发1例

Cancer treatment communications Pub Date : 2015-01-01 DOI:10.1016/j.ctrc.2015.03.001

Khalid Al-Baimani , Harman S. Sekhon , Paul Wheatley-Price

{"title":"间变性淋巴瘤激酶(ALK)阳性腺癌17年后复发1例","authors":"Khalid Al-Baimani , Harman S. Sekhon , Paul Wheatley-Price","doi":"10.1016/j.ctrc.2015.03.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC.</p></div><div><h3>Presentation of case</h3><p>Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later.</p></div><div><h3>Discussion</h3><p>It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis.</p></div><div><h3>Conclusion</h3><p>This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.</p></div>","PeriodicalId":90461,"journal":{"name":"Cancer treatment communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.03.001","citationCount":"5","resultStr":"{\"title\":\"Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report\",\"authors\":\"Khalid Al-Baimani , Harman S. Sekhon , Paul Wheatley-Price\",\"doi\":\"10.1016/j.ctrc.2015.03.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC.</p></div><div><h3>Presentation of case</h3><p>Our case is a 58 year old man who presented initially with stage one ALK positive NSCLC. He relapsed 17 years later.</p></div><div><h3>Discussion</h3><p>It is very unusual for stage one NSCLC to relapse beyond 10 years. It is surprising that our patient relapsed many years after his initial diagnosis.</p></div><div><h3>Conclusion</h3><p>This may highlight a different biology and outcome. It may also mean a longer follow up is needed for this subset of patients.</p></div>\",\"PeriodicalId\":90461,\"journal\":{\"name\":\"Cancer treatment communications\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ctrc.2015.03.001\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2213089615000080\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213089615000080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 5

摘要

约4%至6%的非小细胞肺癌(NSCLC)伴有间变性淋巴瘤激酶重排(ALK)。ALK阳性NSCLC具有明显的临床病理特征。在晚期，ALK酪氨酸激酶抑制剂用于一线和二线治疗。然而，对一期ALK阳性NSCLC的预后知之甚少。我们的病例是一名58岁的男性，最初表现为一期ALK阳性非小细胞肺癌。17年后，他又复发了。一期NSCLC复发超过10年是非常罕见的。令人惊讶的是，我们的病人在最初诊断多年后复发。结论:这可能是一种不同的生物学和结果。这也可能意味着这部分患者需要更长的随访时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report

Introduction

About four to six percent of non-small cell lung cancer (NSCLC) harbor Anaplastic lymphoma kinase rearrangement (ALK). ALK positive NSCLC has a distinct clinicopathological features. In the advanced setting ALK tyrosine kinase inhibitors are used in the first and second line of treatment. However, less is known about the outcome of stage one ALK positive NSCLC.